tbuckley/cabot-search huggingface dataset:
Final results of a prospective randomized trial to evaluate the effectiveness of the Cox-MAZE-III-Operation using cooled-tip radiofrequency ablation in patients with chronic atrial fibrillation and mitral valve disease Krishna Khargi, Thomas Deneke, Peter H. Grewe, Stefan von Dryander, Thomas Lawo, Ellen Schick, J�rgen Barmeyer, Axel Laczkovics, Bernd Lemke. Berufsgenossenschaftliche Kliniken Bergmannsheil - University of Bochum, Bochum, Germany
Journal: Journal of the American College of Cardiology (2001)
Questions and Answers
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study
Authors: Susan Martin, Elena P. Sorokin, E. Louise Thomas, Naveed Sattar, Madeleine Cule, Jimmy D. Bell, Hanieh Yaghootkar
Journal: Diabetes Care (2022)

OBJECTIVE Fat content and volume of liver and pancreas are associated with risk of diabetes in observational studies; whether these associations are causal is unknown. We conducted a Mendelian randomization (MR) study to examine causality of such associations. RESEARCH DESIGN AND METHODS We used genetic variants associated (P &amp;lt; 5 × 10−8) with the exposures (liver and pancreas volume and fat content) using MRI scans of UK Biobank participants (n = 32,859). We obtained summary-level data for risk of type 1 (9,358 cases) and type 2 (55,005 cases) diabetes from the largest available genome-wide association studies. We performed inverse-variance weighted MR as main analysis and several sensitivity analyses to assess pleiotropy and to exclude variants with potential pleiotropic effects. RESULTS Observationally, liver fat and volume were associated with type 2 diabetes (odds ratio per 1 SD higher exposure 2.16 [2.02, 2.31] and 2.11 [1.96, 2.27], respectively). Pancreatic fat was associated with type 2 diabetes (1.42 [1.34, 1.51]) but not type 1 diabetes, and pancreas volume was negatively associated with type 1 diabetes (0.42 [0.36, 0.48]) and type 2 diabetes (0.73 [0.68, 0.78]). MR analysis provided evidence only for a causal role of liver fat and pancreas volume in risk of type 2 diabetes (1.27 [1.08, 1.49] or 27% increased risk and 0.76 [0.62, 0.94] or 24% decreased risk per 1SD, respectively) and no causal associations with type 1 diabetes. CONCLUSIONS Our findings assist in understanding the causal role of ectopic fat in the liver and pancreas and of organ volume in the pathophysiology of type 1 and type 2 diabetes.
Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19
Authors: Jennifer E. Huffman, Guillaume Butler-Laporte, Atlas Khan, Erola Pairo-Castineira, Theodore G. Drivas, Gina M. Peloso, Tomoko Nakanishi, Andrea Ganna, Anurag Verma, J. Kenneth Baillie, Krzysztof Kiryluk, J. Brent Richards, Hugo Zeberg
Journal: Nature Genetics (2022)

Abstract The OAS1/2/3 cluster has been identified as a risk locus for severe COVID-19 among individuals of European ancestry, with a protective haplotype of approximately 75 kilobases (kb) derived from Neanderthals in the chromosomal region 12q24.13. This haplotype contains a splice variant of OAS1 , which occurs in people of African ancestry independently of gene flow from Neanderthals. Using trans-ancestry fine-mapping approaches in 20,779 hospitalized cases, we demonstrate that this splice variant is likely to be the SNP responsible for the association at this locus, thus strongly implicating OAS1 as an effector gene influencing COVID-19 severity.
An isolated total cholesterol level is inadequate
Authors: R. C. Keniston
Journal: JAMA (1989)

<h3>In Reply. —</h3> The letter by Dr Stare takes issue with the Campaign Against Cholesterol announced recently by the American Medical Association (AMA). Dr Stare objects to the campaign on the basis that the cholesterol factor is of minor importance as a risk factor in cardiovascular disease and suggests that our efforts might be directed in different ways. That cholesterol is of minor importance as a risk factor for cardiovascular disease is a subjective opinion. The recent report of the expert panel organized by the National Cholesterol Education Program certainly supports the contention that reducing the level of cholesterol is an important means of reducing morbidity and mortality from cardiovascular disease. Many well-designed studies, including the Lipid Research Clinics Coronary Primary Prevention Trial, the Framingham Study, and the Multiple Risk Factor Intervention Trial, indicate that elevated levels of blood cholesterol contribute to early death from coronary heart disease. In fact,
A Young Woman With Palpitations: A Poison or a Remedy?
Authors: Dinkar Bhasin, Rahul Kumar, Anunay Gupta
Journal: Circulation (2021)

A young woman in her thirties presented to the emergency department with the complaint of palpitations.She was symptomatic for the past 2 hours.She had no previous cardiovascular illness.Her heart rate was 50 beats per minute, and the blood pressure was 110/70 mm Hg.Cardiovascular system examination was unremarkable.The patient denied intake of any medications; however, her husband suspected her to have consumed a poisonous substance after a dispute.The 12-lead ECG is shown in Figure 1.What is the diagnosis?Please turn the page to read the diagnosis.Figure 1.12-Lead ECG at presentation.
Mineral metabolism of astronauts.
Journal: BMJ (1971)

phenylketonuria sometimes discloses hitherto unrecognized hyperphenylalaninaemia.8 9 In the absence of any authorita- tive answer to the question of treatment, it seems reasonable to treat all infants, whose serum levels exceed 15 mg/100 ml when fasting, or after a normal feed, or after loading, and who excrete the characteristic metabolites in the urine when their serum level exceeds 15 mg/100 ml.
Vasomotor Nephropathy
Authors: Leonard B. Berman
Journal: JAMA (1975)

FEW syndromes have had as many names and periodic rediscoveries as acute tubular necrosis. The 1940s produced "lower nephron nephrosis," and after that "hemoglobinuric nephrosis," "crush kidney," and "acute tubular necrosis"; all made their debut. Recently, "vasomotor nephropathy" was proposed, thus completing a circle back to 1917 when the same syndrome was studied by German investigators and called "vasomotor nephritis." This parade of names clearly illustrates changing concepts of pathogenesis. Specifically, we are now leaving the era of acute tubular necrosis, a term that emphasized minor morphological changes in the tubules as pathogenetic, and we are entering an era in which persistent renal cortical vasoconstriction (angiotensin-induced?) is regarded as the central defect. In any case, and by whatever name, we are speaking of the reversible acute renal failure, which follows various kinds of shock or certain other insults and is accompanied by relatively minor morphological change in the kidney. A
Outcome of patients with acute coronary syndromes with and without prior CABG: Results from the PURSUIT trial Marino Labinaz, Rakhi Kilaru, Karen Pieper, Steven P. Marso, Lisa Berdan, Michael Kitt, Maarten L. Simoons, Robert M. Califf, Eric J. Topol, Robert A. Harrington, Paul W. Armstrong, for the PURSUIT Investigators. University of Ottawa Heart Institute, Ottawa, ON, Canada, Duke University Medical Center, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study
Authors: Bharati Kochar, Juulia Jylhävä, Jonas Söderling, Christine S. Ritchie, Jonas F. Ludvigsson, Hamed Khalili, Ola Olén, Malin Olsson, Henrik Hjortswang, Pär Myrelid, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Michael Eberhardson, Caroline Nordenvall, Jan Björk, Ulrika L. Fagerberg, Martin Rejler, Olof Grip, Pontus Karling, Jonas Halfvarson
Journal: Clinical Gastroenterology and Hepatology (2022)
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos<i>et al</i>
Authors: Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
Journal: Annals of the Rheumatic Diseases (2021)
Is peripheral endothelium-dependent flow-mediated vasodilatation associated with left ventricular mass in older persons with hypertension? Jidong Sung, Anita C. Bacher, Katherine L. Turner, Jamie R. DeRegis, Paul S. Hees, Harry A. Silber, Edward P. Shapiro, Pamela Ouyang, Kerry J. Stewart. Johns Hopkins School of Medicine, Baltimore, MD
Journal: Journal of the American College of Cardiology (2001)
Association News
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extracellular ATP and UTP stimulate release of tissue-type plasminogen activator from vascular endothelium in human forearm David Erlinge, Th�rd�s Hrafnkelsd�ttir, Sverker Jern. Dept of Cardiology, Lund, Sweden, Dept of Clin. Exp. Research, Gothenburg, Sweden
Journal: Journal of the American College of Cardiology (2001)
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Authors: Jianwei Qu, Haimeng Yan, Yifan Hou, Wen Cao, Yang Liu, Enfan Zhang, Jingsong He, Zhen Cai
Journal: Journal of Hematology & Oncology (2022)

RNA demethylase ALKBH5 takes part in the modulation of N
Relations of Uterine to Constitutional Disorder
Authors: F. W. Mackenzie
Journal: BMJ (1852)

UTERINE TO CONBTIWUTIONAL DlUOiDEBR.28 by the fact of no bile being detectable in the blood, even after the liver has been extirpated, as tested by Hernde.We have already seen that bile is essential to the formation of chyle, that is, essential to the life of the animal; and that the characteristic of chyle as distinguished from chyme, is the presence of oil globules and molecules of fat.Do we, then, push our argument too far in saymg, that hydrogen is the peculiarly essential element in oil necessary to the nutritive and regen- erative powers, seeing that the grand characteristic of oil is, that it is of all animal substances the richest in hydrogen.We have thus endeavoured to show;.1.That the main office of the liver is not to excrete hydrocarbonaceous matters, the result of the waste of the tissues; and there- fore that its function is not vicarious with that of the lungs.2. That the grand function of the liver is to create bile, without which bile the nutrition of the animal is impossible.S. That the grand office of the bile is to create the oil globules and fat molecules, as they are found in the chyle.4. That tlhis oil is of a character different from ordinary oils, inas- much as it is not only the most nutritious of all oils hitherto tested (cod-liver oil), but is, in short, an oil essential to the formative and regenerative processes (oil of chyle).5. That in proportion to the relative size of the liver in the animal series, will be found the force of the formative and regenera- tive powers.6.That although oxygen is essential to the vital force, yet one of its grand offices is to destroy tissues; and thus an antayoninm may be said to subsist between the functions of the lungs and the liver.7.That the liver has the power of decomposing water, and using the hydrogen thus set free for the creation of bile.8. That, therefore, as the lungs may be called the oxygenators in animals, so the liver inay be calld the hydroyenator in animal.
Abstract 146: Adenosine Production by Biomaterial-supported Mesenchymal Stromal Cells Reduces the Innate Inflammatory Response in Myocardial Ischemia/Reperfusion Injury
Authors: Eric Y Shin, Lanfang Wang, Marina Zemskova, Juline Deppen, Kai Xu, Andrés J Garcia, Rabindra Tirouvanziam, Rebecca D Levit
Journal: Circulation Research (2017)

Rationale: During myocardial ischemia/reperfusion (MI/R) injury there is excessive release of immunogenic metabolites that activate cells of the innate immune system. These metabolites include adenine nucleotides such as adenosine triphosphate (ATP) and adenosine monophosphate (AMP) which up-regulate chemotaxis, migration, and effector function of early infiltrating inflammatory cells. These cells subsequently drive further tissue devitalization. Mesenchymal stromal cells (MSCs) are a potential treatment modality for MI/R due to their powerful anti-inflammatory capabilities; however, the manner in which they regulate the acute inflammatory milieu requires further elucidation. Surface membrane ecto-5’-nucleotidase CD73 may play a critical role in inflammatory regulation by converting pro-inflammatory AMP to anti-inflammatory adenosine (ADO). We hypothesized that the MSC-mediated conversion of AMP into ADO reduces inflammation in early MI/R, favoring a micro-environment that attenuates excessive innate immune cell activation and facilitates earlier cardiac recovery. Objective: To determine the contribution of MSC-mediated production of ADO in regulating the innate inflammatory response following MI/R. Methods and Results: Adult rats were subjected to 30 minutes of MI/R injury. MSCs were encapsulated within a hydrogel vehicle and implanted onto the myocardium. A subset of MSCs were treated with the CD73 inhibitor, α,β-methylene adenosine diphosphate, prior to implantation. Using liquid chromatography/mass spectrometry, we found MSCs increase myocardial ADO availability following injury via CD73 activity. We also demonstrated that MSCs reduce innate immune cell infiltration as measured by flow cytometry and hydrogen peroxide formation as measured by Amplex Red assay. These effects were also dependent on MSC-mediated CD73 activity. Furthermore, through echocardiography we found CD73 activity on MSCs was critical to optimal protection of cardiac function following MI/R injury. Conclusion: MSC-mediated conversion of AMP to ADO by CD73 ecto-5’-nucleotidase activity exerts a powerful anti-inflammatory effect following MI/R injury.
Updated results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery.
Authors: Zheng Wu, Zheng Wang, Lei Zhang, Xiaojing Song, Xilin Du, Kai Tan
Journal: Journal of Clinical Oncology (2022)

445 Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and a leading cause of tumor related death. Hepatectomy is considered to be the main radical treatment for HCC. However, the high recurrence rate remains a major challenge. Adjuvant therapy to effectively reduce recurrence is particularly important for patients (pts) with high recurrence factors. Transarterial chemoembolization (TACE) as adjuvant therapy for pts with high recurrence risk factors after hepatectomy is recommended in several guidelines, but the effect is still unsatisfactory. Here, we updated the results of ALTER-H004 which aimed to evaluate the efficacy and safety of anlotinib as maintenance adjuvant treatment following inductional TACE in pts with HCC. Methods: Pts with histologically confirmed HCC and undertook hepatectomy within 1-2 months will be recruited in this study. The recruited pts who did not recieve any previous tumor-related treatment must have any of the following high risk factors: ≥5 cm and &lt; 10 cm of tumor diameter, tumor number ≥3, tumor microvascular invasion M1 or M2, portal vein tumor thrombus resection (Cheng's classification I/II). Eligible pts received conventional TACE treatment with pirarubicin and platinum within 1-2 months after hepatectomy. On the 4th day after TACE treatment, oral anlotinib (12mg, qd, 2 weeks on 1 week of) was given until disease recurrence or unacceptable toxicity. The calculated sample size was 48. The primary endpoint was disease free survival (DFS). Secondary endpoints were 1-year DFS rate, time to recurrence and safety. Results: As of September 14, 2021, 24 pts were enrolled and 23 pts received at least once tumor assessment. According to RECIST 1.1, 17 of 24 did not progress were still on treatment and 5 relapsed. One withdrew the consent and 1 discontinued because of intolerable adverse events. The longest duration of treatment is 15.24 months. The DFS were not mature and the 6-month DFS rates were 75.11% (95% CI: 46.28̃89.91). 12 of 24 pts (50.0%) experienced treatment-related adverse events (TRAEs). Grade 3 TRAEs occurred in 4 pts (16.7%) included hypertension (29.2%), hyperbilirubinemia and hematologic toxicities. No grade 4 or 5 TRAEs occurred. Conclusions: Preliminary results suggested that anlotinib combined with TACE as adjuvant therapy in HCC pts at high recurrence risk exhibited encouraging efficacy and manageable adverse events, which should be validated in more pts consecutively. Clinical trial information: NCT04213118.
TCT-76 Percutaneous Ventricular Restoration (PVR) therapy using the Parachute® Device in Patients with Ischemic Dilated Heart Failure: PARACHUTE III, European Post Market Trial, Primary Endpoint Results
Authors: Martyn Thomas, Christoph A. Nienaber, Hüseyin Ince, Andrejs Erglis, Vladan Vukcevic, Ulrich Schäfer, Rui C. Ferreira, Corrado Tamburino
Journal: Journal of the American College of Cardiology (2014)
Serial changes of left ventricular function in dogs following myocardial ischemia-reperfusion injury: A real-time 3-dimensional echocardiographic assessment Jian Xin Qin, Takahiro Shiota, Marta Sitges, Kai Wang, Zhongmin Zhou, Xiaorong Zhou, XiYi Hang, Yong Jin Kim, Fabrice Bauer, Neil L. Greenberg, James D. Thomas. The Cleveland Clinic Foundation, Cleveland
Journal: Journal of the American College of Cardiology (2001)
Miscellany.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Parenteral cephalosporins
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PARIS
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal